Fuso Pharmaceutical Industries (4538) · InitiativeRestatedLatest Financial results briefing materials (2026-05-12): "Advanced"
Japan-exclusive development and sales license for an FSGS drug candidate
First written in FY2025. 1 of 3 entries say "Restated". Latest entry: 2026-05-12.
3entries
2years
1from disclosures
How it moved
Same theme, other companies
Exclusive Japanese development and marketing licence for DMX-200 (FSGS drug candidate)A theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-05-12AdvancedFinancial results briefing materials
「Japan (from May 2025)」
The company specifically disclosed the timing of the Phase 3 trial of DMX-200 in Japan and its participation in the international joint trial. - FY2026-H1RestatedAnnual report
「Dimerix Limited Australia License agreement for exclusive development and sales rights in Japan for a drug candidate compound for focal segmental glomerulosclerosis (FSGS) (development code: DMX-200) Upfront fee Milestone payments, etc.」
The company continues to disclose its license agreement for exclusive development and sales rights in Japan for DMX-200. It also describes an increase in research and development expenses associated with progress in R&D activities. - FY2025First statedAnnual report
「Dimerix Limited Australia License agreement for exclusive development and sales rights in Japan for a drug candidate compound for focal segmental glomerulosclerosis (FSGS) Upfront fee Milestone payments, etc.」
The company has entered into a license agreement with Dimerix Limited to obtain exclusive development and sales rights in Japan for a drug candidate compound for FSGS. The agreement provides for an upfront fee and milestone payments, among other items.